PD-11 In depth analysis of label-free infrared (IR) imaging-based microsatellite instability (MSI) classification in early colon cancer (CC) on samples from the AIO ColoPredictPlus 2.0 (CPP) registry trial
Authors: K. Gerwert, S. Schörner, F. Großerueschkamp, A. Kraeft, D. Schuhmacher, C. Lugnier, V. Heuer, C. Teschendorf, L. Mueller, A. Mosig, D. Arnold, A. Reinacher-Schick
Journal: Annals of Oncology (2022)

MSI occurs in 15-20% of all early CC due to a deficient mismatch repair system and testing is now considered standard for all colon cancers as MSI is of prognostic and predictive value. Presently, protein analysis using immunohistochemistry targeting the mismatch repair proteins is most frequently used in routine clinical pathology with high sensitivity. Alternatively, fragment length analysis of microsatellite loci or next-generation sequencing can be used. All the techniques referred to are time and tissue consuming. We utilize label-free quantum cascade laser (QCL) based IR imaging combined with artificial intelligence (AI) approaches to test unstained tissue samples for MSI. IR imaging is an emerging microscopic technique based on the interaction of electromagnetic waves with the molecules within the tissue creating molecular fingerprints. To establish the methodological robustness of our approach, we analyzed samples from the multicentric prospective AIO ColoPredict Plus (CPP) 2.0 registry trial. IR imaging can analyze unstained paraffin-embedded tissue slides within an average of 30 min/slide. All tissue samples were obtained from the CPP registry trial. For development of the MSI/MSS classification model the cohort was split into a training, test, and validation set. The training set was utilized for the optimization of a modified VGG-16 convolutional neural network (CNN) with area under receiver operating characteristic (AUROC) and area under precision recall curve (AUPRC) evaluated on the test set as endpoints. The final classification model is validated on the validation set and in depth analyzed for sub-cohorts (BRAF, KRAS, UICC stage, grading). A cohort of 547 patients (training n=331 (43% MSI), test n=69 (43% MSI), validation n=147 (18% MSI)) was selected from CPP. Baseline characteristics including BRAF mutations, were balanced between training and test set, thus providing a balanced ground-truth for the training of the classifier. By contrast, the validation set (18% MSI) corresponds to the natural occurrence of MSI, showing a typically pattern for MSI and MSS with a higher proportion of female patients, more right-sided cases and more BRAF mutations for MSI-samples. The selected MSI/MSS classifier reached a validation AUROC of 0.90 (sensitivity 85%, specificity 84%) and AUPRC of 0.74. The AUROC of the sub-cohorts range between 0.78 and 0.99 (BRAF: 0.93 (wt), 0.78 (mt); KRAS: 0.84 (wt), 0.99 (mt); Grading: 0.93 (G2), 0.84 (G3); UICC Staging: 0.93 (II), 0.86 (III)). AI integrated IR imaging demonstrates a reliable classification performance for MSI/MSS with an AUROC of 0.90 (sensitivity 85%, specificity 84%) and robustness over sub-cohorts e.g., BRAF, KRAS, or staging. It further approaches the performance of the present gold standard immunohistochemistry. The combination of spatial and biochemical information encoded in the IR images allows CNNs to track changes on the molecular level. Additionally, this method requires fewer samples than other AI approaches and maintains intact tissue for further molecular analysis. Overall, this method has the potential to become an applicable diagnostic tool beyond the scope of known biomarkers for tumor-agnostic assessments.